Client-selected organoids screened with or without allogeneic MHC-matched PBMCs, tailored to your research needs. A variety of compound classes can be screened ranging from small molecules to biologics, viral vectors, cell engagers, and cellular therapies.
Predefined models for routine screening in organoids containing actionable alterations across cancer types. Compounds can be screened alone and in combinations, providing a rapid and cost-effective alternative to in vivo preclinical animal experiments.
Characterize cell populations of interest with precision–identify and validate complex signatures and identify biomarkers of therapeutic response
Uncover spatio-temporal patterns of gene expression in two dimensions to better characterize the relationships between molecular profiles and therapeutic response
Arrant establishes joint research teams combining disciplines from its bio-repository, computational biology, medical, bioinformatics, and machine learning to work alongside your teams with a goal of accelerating CDx development.